Elite in B-Cell Lymphoma

Tom V. Van Meerten

Groningen, GR, NL 
Elite in B-Cell Lymphoma
Groningen, GR, NL 
OverviewLocationsClinical Research

Overview

Tom Van Meerten practices in Groningen, Netherlands. Mr. Van Meerten is rated as an Elite expert by MediFind in the treatment of B-Cell Lymphoma. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), and Diffuse Large B-Cell Lymphoma (DLBCL).

His clinical research consists of co-authoring 76 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 37 articles and participated in 1 clinical trial in the study of B-Cell Lymphoma.

Gender
Male

Locations

Groningen, GR, Netherlands
Other Locations
Utrecht, UT, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Enrollment Status: Completed
Publish Date: December 01, 2025
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine
Study Phase: Phase 3
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Biological
Study Drugs: Brexucabtagene Autoleucel, Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel
Study Phase: Phase 2
View 1 Less Clinical Trial

76 Total Publications

Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.
Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.
Journal: Nature communications
Published: September 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Van Meerten's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile